Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors : A Promising Approach to Combat Tuberculosis
Abstract Tuberculosis is a prominent aliment throughout the world and a leading cause of mortality among infectious diseases. Drug development for multi‐drug resistance and reducing the current therapy time is the top priority. Mycobacterial membrane protein large 3 (MmpL3) is a promising target with high potential, however, it has not been explored to its greatest potential. It is a membrane transporter that translocates trehalose‐monomycolate which is a precursor for the synthesis of mycolic acid that is essential for the synthesis of the bacterial cell wall and is pathogenic in nature. In this review, we have discussed the current development of MmpL3 inhibitors, different scaffolds, their derivatives, and their synthetic schemes and provide insight into the challenges in developing these inhibitors..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
ChemMedChem - 16(2021), 20, Seite 3136-3148 |
| Beteiligte Personen: |
Umare, Mohit D. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Wiley‐VCH GmbH |
|---|
| Umfang: |
13 |
|---|
| doi: |
10.1002/cmdc.202100359 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003679659 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003679659 | ||
| 003 | DE-627 | ||
| 005 | 20230307131023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cmdc.202100359 |2 doi | |
| 028 | 5 | 2 | |a CMDC_CMDC202100359.xml |
| 035 | |a (DE-627)WLY003679659 | ||
| 035 | |a (WILEY)CMDC202100359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 540 |a 610 |q ASE |
| 082 | 0 | 4 | |a 540 |a 610 |q ASE |
| 084 | |a 44.42 |2 bkl | ||
| 084 | |a 35.07 |2 bkl | ||
| 084 | |a 58.28 |2 bkl | ||
| 100 | 1 | |a Umare, Mohit D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors |b A Promising Approach to Combat Tuberculosis |
| 264 | 1 | |c 2021 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Wiley‐VCH GmbH | ||
| 520 | |a Abstract Tuberculosis is a prominent aliment throughout the world and a leading cause of mortality among infectious diseases. Drug development for multi‐drug resistance and reducing the current therapy time is the top priority. Mycobacterial membrane protein large 3 (MmpL3) is a promising target with high potential, however, it has not been explored to its greatest potential. It is a membrane transporter that translocates trehalose‐monomycolate which is a precursor for the synthesis of mycolic acid that is essential for the synthesis of the bacterial cell wall and is pathogenic in nature. In this review, we have discussed the current development of MmpL3 inhibitors, different scaffolds, their derivatives, and their synthetic schemes and provide insight into the challenges in developing these inhibitors. | ||
| 700 | 1 | |a Khedekar, Pramod B. |4 aut | |
| 700 | 1 | |a Chikhale, Rupesh V. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |g 16(2021), 20, Seite 3136-3148 |w (DE-627)WLY003672778 |x 18607187 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:20 |g pages:3136-3148 |g extent:13 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.42 |q ASE |
| 936 | b | k | |a 35.07 |q ASE |
| 936 | b | k | |a 58.28 |q ASE |
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 20 |h 3136-3148 |g 13 | ||